Literature DB >> 29045267

The Prevalence and Investigation of Risk Factors of Oral Mucositis in a Pediatric Oncology Inpatient Population; a Prospective Study.

Gabrielle Allen1, Richard Logan2, Tom Revesz3, Dorothy Keefe4,5, Sam Gue1,2.   

Abstract

BACKGROUND: Oral mucositis can be a frequent and severe complication of chemotherapy in children. It can result in pain, infection, depression, prolonged admission, treatment delays, increase in patient morbidity, and increased costs. AIM: To record the prevalence and severity of oral mucositis among inpatients and explore the relationship of risks factors and the development of oral mucositis.
DESIGN: During an 18-month period 643 clinical inpatient assessments were completed on 73 children who were admitted and had received chemotherapy in the last 14 days.
RESULTS: There were 43 episodes of oral mucositis in 31 children; 42.5% of the inpatient population. World Health Organization assessment identified 32.6% of episodes were grade 1, 34.9% grade 2, 14.0% grade 3, and 18.6% grade 4. Analysis revealed significant associations between patient diagnosis (P<0.0001), chemotherapy cycles (P<0.0001), day 8 and 9 of the chemotherapy cycle (P<0.05), and neutropenia (P<0.0001) and oral mucositis. Children had increased length of admission with increasing severity of oral mucositis (P=0.0005).
CONCLUSIONS: The prevalence of oral mucositis was 42.5% among inpatients and admission length was increased with increasing severity. Patient diagnosis, chemotherapy treatment block, day of chemotherapy cycle, and neutropenic status were shown to influence the risk of developing oral mucositis.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29045267     DOI: 10.1097/MPH.0000000000000970

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  5 in total

1.  Integrated oral care contributes positively to the course of treatment of oncopediatric patients.

Authors:  Isabella Lima Arrais Ribeiro; Ricardo Dias de Castro; Raphael Cavalcante Costa; Lecidâmia Cristina Leite Damascena; Nyellisonn Nando Nóbrega de Lucena; Paula Maria Bezerra Maracajá; Fabio Gomes Dos Santos; Eliane Batista de Medeiros Serpa; Simone Alves Sousa; Ana Maria Gondim Valença
Journal:  Eur J Pediatr       Date:  2021-03-22       Impact factor: 3.183

2.  Incidence and risk factors for oral mucositis in pediatric patients receiving chemotherapy.

Authors:  Marina Curra; Amanda F Gabriel; Maria Beatriz C Ferreira; Marco Antonio T Martins; André T Brunetto; Lauro J Gregianin; Manoela Domingues Martins
Journal:  Support Care Cancer       Date:  2021-04-12       Impact factor: 3.603

3.  The effects of a combination oral spray (Mucosamin®) for the prevention of oral mucositis in pediatric patients undergoing hematopoietic stem cell transplantation: a double blind randomized clinical trial.

Authors:  Marzieh Shahrabi; Mohammad Solduzian; Molouk Hadji Babaie; Seied Asadollah Mousavi; Navid Goodarzi; Nazanin Shabani Ravari; Kourosh Sadeghi
Journal:  Support Care Cancer       Date:  2022-06-23       Impact factor: 3.359

4.  The Implementation of an Integrated Oral Care Protocol for Pediatric Cancer Patients: a Qualitative Study.

Authors:  Isabella Lima Arrais Ribeiro; Maria do Carmo Gullaci Guimarães Caccia-Bava; Maria Eduarda Alves Sampaio; Rebecca Rhuanny Tolentino Limeira; Laís Guedes Alcoforado de Carvalho; Fabio Gomes Dos Santos; Paula Maria Maracajá Bezerra; Simone Alves Sousa; Ana Maria Gondim Valença
Journal:  J Cancer Educ       Date:  2022-08-27       Impact factor: 1.771

5.  Severe oral mucositis relating to pain and worse oral condition among patients with solid tumors undergoing treatment with FOLFIRI and 5-FU: a retrospective study.

Authors:  Laura Costa de Almeida; Bernardo da Fonseca Orcina; Aloizio Premoli Maciel; Dayanne Dos Santos; Brena Rodrigues Manzano; Paulo Sérgio da Silva Santos
Journal:  Sao Paulo Med J       Date:  2022 Jul-Aug       Impact factor: 1.838

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.